Paterson I C, Matthews J B, Huntley S, Robinson C M, Fahey M, Parkinson E K, Prime S S
Division of Oral Medicine, Pathology and Microbiology, University of Bristol, Lower Maudlin Street, Bristol, BS1 2LY, UK.
J Pathol. 2001 Apr;193(4):458-67. doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH822>3.0.CO;2-V.
This study examined the immunocytochemical expression of the transforming growth factor-beta (TGF-beta) isoforms TGF-beta1, TGF-beta2, and TGF-beta3, together with the TGF-beta cell surface receptors TbetaR-I and TbetaR-II, in patient-matched tissue pairs of normal human oral epithelium, primary squamous cell carcinomas, and metastatic lymph node tumour deposits. There were no significant differences in the intensity of TGF-beta isoform specific staining between the normal oral epithelium, the primary tumours, and the lymph node metastases. By contrast, there was significantly less TbetaR-II in the metastases than in the primary tumour and between the primary tumour and the normal oral epithelium. Similar trends were evident with TbetaR-I, but not at a statistically significant level. This study also examined the structure of TbetaR-I and TbetaR-II in normal human oral keratinocytes in vitro and in 14 human oral carcinoma cell lines with known responses to TGF-beta1. No structural abnormalities of TbetaR-II were present in the normal keratinocytes or in 13 of 14 malignant cell lines; in one line, there were both normal and mutant forms of TbetaR-II, the latter being in the form of a frameshift mutation with the insertion of a single adenine base (bases 709-718, codons 125-128), predicting a truncated receptor having no kinase domain. No defects were present in TbetaR-I. The structures of TbetaR-I and TbetaR-II did not correlate with growth inhibition by TGF-beta1. The data suggest that decreased expression of TGF-beta receptors, rather than structural defects of these genes, may be important in oral epithelial tumour progression. In order to examine the functional significance of a specific decrease in TbetaR-II expression, a dominant-negative TbetaR-II construct (dnTbetaR-II) was transfected into a human oral carcinoma cell line with a normal TGF-beta receptor profile and known to be markedly inhibited by TGF-beta1. In those clones that overexpressed the dnTbetaR-II, growth inhibition and Smad binding activity were decreased, whilst the regulation of Fra-1 and collagenase-1 remained unchanged following treatment with TGF-beta1. The results demonstrate that a decrease in TbetaR-II relative to TbetaR-I leads to selective gene regulation with loss of growth inhibition but continued transcription of AP-1-dependent genes that are involved in the regulation of the extracellular matrix.
本研究检测了转化生长因子-β(TGF-β)亚型TGF-β1、TGF-β2和TGF-β3,以及TGF-β细胞表面受体TβR-I和TβR-II在正常人口腔上皮、原发性鳞状细胞癌和转移性淋巴结肿瘤沉积物的患者匹配组织对中的免疫细胞化学表达。在正常口腔上皮、原发性肿瘤和淋巴结转移灶之间,TGF-β亚型特异性染色强度没有显著差异。相比之下,转移灶中的TβR-II明显少于原发性肿瘤,且原发性肿瘤与正常口腔上皮之间也存在差异。TβR-I也有类似趋势,但未达到统计学显著水平。本研究还检测了正常人口腔角质形成细胞以及14种已知对TGF-β1有反应的人类口腔癌细胞系中TβR-I和TβR-II的结构。正常角质形成细胞或14种恶性细胞系中的13种中不存在TβR-II的结构异常;在一个细胞系中,存在正常和突变形式的TβR-II,后者为移码突变形式,插入了单个腺嘌呤碱基(第709 - 718位碱基,密码子125 - 128),预测为无激酶结构域的截短受体。TβR-I没有缺陷。TβR-I和TβR-II的结构与TGF-β1介导的生长抑制无关。数据表明,TGF-β受体表达降低而非这些基因的结构缺陷,可能在口腔上皮肿瘤进展中起重要作用。为了研究TβR-II表达特异性降低的功能意义,将显性负性TβR-II构建体(dnTβR-II)转染到具有正常TGF-β受体谱且已知对TGF-β1有明显抑制作用的人类口腔癌细胞系中。在那些过表达dnTβR-II的克隆中,生长抑制和Smad结合活性降低,而在用TGF-β1处理后,Fra-1和胶原酶-1的调节保持不变。结果表明,相对于TβR-I,TβR-II的减少导致选择性基因调节,生长抑制丧失,但参与细胞外基质调节的AP-1依赖性基因持续转录。